Arkuda Therapeutics is advancing novel targeted medicines for the treatment of frontotemporal dementia.
Location: United States, Massachusetts, Watertown
Total raised: $108M
Investors 3
| Date | Name | Website |
| - | Mission Bi... | missionbio... |
| - | Atlas Vent... | atlasventu... |
| 05.11.2022 | NFLS - Piv... | pivotalbio... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 15.02.2022 | Series B | $64M | - |
| 08.11.2019 | Series A | $44M | - |
Mentions in press and media 11
| Date | Title | Description | Source |
| 15.02.2022 | Arkuda Therapeutics Raises $64M in Series B Financing | Arkuda Therapeutics, a Watertown MA-based biotechnology company, raised $64M in Series B funding. T... | finsmes.co... |
| 10.02.2022 | Neuro-focused Arkuda raises $64M as dementia drug moves clos... | Neurodegenerative disease drug developer Arkuda Therapeutics aims to treat brain diseases by address... | medcitynew... |
| 10.02.2022 | Arkuda Therapeutics Receives $64M Series B | WATERTOWN, MA, Arkuda Therapeutics today announced the completion of a $64 million Series B financ... | vcnewsdail... |
| 10.02.2022 | Arkuda Therapeutics Raises $64 Million Series B Financing to... | WATERTOWN, Mass., Feb. 10, 2022 /PRNewswire/ -- Arkuda Therapeutics, a biotechnology company applyin... | marketscre... |
| 24.04.2020 | Laura Shawver on why she came back after an $88M windfall... | Laura Shawver Laura Shawver didn’t quite understand cancer until she had it. By that point, ... | endpts.com... |
| 08.11.2019 | Arkuda Therapeutics Raises $44M in Series A Financing | Arkuda Therapeutics, a Cambridge, Mass.-based company leveraging new insights into progranulin and l... | finsmes.co... |
| 08.11.2019 | Arkuda Therapeutics Inks $44M Series A | CAMBRIDGE, MA, Arkuda Therapeutics announced the completion of a $44 million Series A financing. ... | vcnewsdail... |
| 07.11.2019 | Arkuda Therapeutics Closes $44M Series A | Arkuda Therapeutics, a company leveraging new insights into progranulin and lysosomal biology to dev... | citybizlis... |
| 07.11.2019 | Arkuda bags $44M to target progranulin and head off inherite... | It’s a common refrain in dementia studies: “We should have treated them earlier.” It’s why treating ... | fiercebiot... |
| 07.11.2019 | Arkuda bags $44M to target progranulin and head off inherite... | It’s a common refrain in dementia studies: “We should have treated them earlier.” It’s why treating ... | fiercebiot... |
Show more